排除了 2 家大型药品福利管理公司的 2012 年至 2015 年有可用仿制药替代的品牌药物的医疗保险支出和潜在节省。
Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.
机构信息
Collaboration for Research Integrity and Transparency, Yale University, New Haven, Connecticut.
Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
出版信息
JAMA Intern Med. 2018 Apr 1;178(4):567-569. doi: 10.1001/jamainternmed.2017.8016.
Abstract
This study uses Medicare Part D drug utilization and spending data to estimate potential Part D program and beneficiary savings on brand-name medications excluded by pharmacy benefit managers for which generic substitutes are available.
摘要
本研究利用医疗保险部分 D 药物利用和支出数据，估算药房福利管理机构排除的、有通用替代品的品牌药物对部分 D 计划和受益人的潜在节省。
相似文献
1
Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.排除了 2 家大型药品福利管理公司的 2012 年至 2015 年有可用仿制药替代的品牌药物的医疗保险支出和潜在节省。
JAMA Intern Med. 2018 Apr 1;178(4):567-569. doi: 10.1001/jamainternmed.2017.8016.
2
Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.医疗保险支出在品牌组合药物与它们的通用成分上的对比。
JAMA. 2018 Aug 21;320(7):650-656. doi: 10.1001/jama.2018.11439.
3
Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.品牌药物和医疗保险部分 D：眼科护理提供者的处方模式如何影响成本。
Ophthalmology. 2018 Mar;125(3):332-339. doi: 10.1016/j.ophtha.2017.05.024. Epub 2017 Jun 16.
4
Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.医疗保险D部分药物替代相关的潜在节省：糖尿病研究转化为行动（TRIAD）研究
J Gen Intern Med. 2014 Jan;29(1):230-6. doi: 10.1007/s11606-013-2546-6. Epub 2013 Aug 22.
5
Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.医疗保险计划 D 中患者和付款人的专利品牌药与授权仿制药使用激励因素
JAMA Intern Med. 2021 Dec 1;181(12):1605-1611. doi: 10.1001/jamainternmed.2021.5997.
6
In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.在医疗保险处方药部分 D 计划中，较低或零共付额和其他鼓励使用通用他汀类药物的特性可以节省数十亿美元。
Health Aff (Millwood). 2012 Oct;31(10):2266-75. doi: 10.1377/hlthaff.2012.0019.
7
Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.医疗保险处方药福利下建议的通用治疗替代方案的成本变异性。
J Manag Care Spec Pharm. 2014 Mar;20(3):283-90. doi: 10.18553/jmcp.2014.20.3.283.
8
Encouraging generic use can yield significant savings.鼓励使用仿制药可大幅节省成本。
Find Brief. 2012 Nov;15(8):1-3.
9
Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.医疗保险处方药部分和医疗补助受益人与延长释放与即刻释放药物制剂相关的经济负担。
JAMA Netw Open. 2020 Feb 5;3(2):e200181. doi: 10.1001/jamanetworkopen.2020.0181.
10
Potential impact of pharmacist interventions to reduce cost for Medicare Part D beneficiaries.药剂师干预措施对降低医疗保险D部分受益人的成本的潜在影响。
J Pharm Pract. 2013 Jun;26(3):248-52. doi: 10.1177/0897190012465983. Epub 2012 Nov 25.
引用本文的文献
1
Improved Glaucoma Medication Access Through Pharmacy Partnership: A Single Institution Experience.通过药房合作改善青光眼药物可及性：单机构经验
Clin Ophthalmol. 2024 Apr 2;18:981-987. doi: 10.2147/OPTH.S450629. eCollection 2024.
2
Generic Drugs in the United States: Policies to Address Pricing and Competition.美国的仿制药：解决定价和竞争问题的政策。
Clin Pharmacol Ther. 2019 Feb;105(2):329-337. doi: 10.1002/cpt.1314. Epub 2019 Jan 10.
3
Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin.品牌阿托伐他汀在仿制药阿托伐他汀推出后的使用和支出趋势。
JAMA Intern Med. 2018 May 1;178(5):719-721. doi: 10.1001/jamainternmed.2018.0990.
本文引用的文献
1
Estimation of Potential Savings Through Therapeutic Substitution.通过治疗性替代估计潜在节省。
JAMA Intern Med. 2016 Jun 1;176(6):769-75. doi: 10.1001/jamainternmed.2016.1704.
Zotero 插件